Updates are available Correction dated 2021-09-29
Click to view Correction: https://doi.org/10.1038/S43588-021-00146-4
-
Authors
Massimino, Luca http://orcid.org/0000-0003-3975-9148
Lamparelli, Luigi Antonio http://orcid.org/0000-0002-9571-2582
Houshyar, Yashar
D’Alessio, Silvia
Peyrin-Biroulet, Laurent
Vetrano, Stefania
Danese, Silvio
Ungaro, Federica http://orcid.org/0000-0001-5395-7795
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (853995 to SV, 853995 to SD)
Fondazione Cariplo (2018-0112 to FU)
Fondazione Amici ONLUS ITALIA, research prize to FU
-
License Information
Text and Data Mining valid from 2021-08-01
Version of Record valid from 2021-08-20
-
More Information
Article History
Received: 30 April 2021
Accepted: 16 July 2021
First Online: 20 August 2021
Change Date: 29 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/S43588-021-00146-4
Competing interests
: S.D. has served as a speaker, consultant and advisory board member for Schering-Plough, Abbott (AbbVie) Laboratories, Merck and Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alfa Wasserman, Genentech, Grunenthal, Pfizer, AstraZeneca, Novo Nordisk, Vifor and Johnson & Johnson. The other authors declare no competing interests.
